H.R. 9699, Transparency & Accountability Mandate. Quorum's AI analysis reads it as a net benefit — and names who gains.
H.R. 9699 · Net good
What it does
This bill requires the Department of Health and Human Services to publicly release all documents, contracts, and communications related to drug pricing agreements struck between the federal government and pharmaceutical manufacturers since January 20, 2025—including deals involving most-favored-nation pricing, direct-to-consumer sales, import duty exemptions, and special regulatory treatment. The bill names 17 specific manufacturers with whom such agreements were announced, mandates disclosure within 30 days, and requires Congress and independent auditors to analyze the economic and budgetary effects of these deals on drug prices and federal programs.
The analysis did not isolate a single beneficiary class.
The trade-off
Disclosure of 'proprietary pricing information' may be heavily redacted under permitted withholdings, potentially limiting the transparency benefit if manufacturers claim broad confidentiality protections under foreign law or settlement agreements.
Transparency scores 85%, with a medium warning level and no provisions unrelated to the bill's subject.
Who is behind it
Filed by Judy Chu. Cosponsored by André Carson, Betty McCollum, Brad Schneider and Chris Pappas.